An open trial of topiramate in the treatment of generalized social phobia

Journal of Clinical Psychiatry

Volumn 65, Issue 12, 2004, Pages 1674-1678

  Van Ameringen, Michael ^a,b   Mancini, Catherine ^a,b   Pipe, Beth ^b   Oakman, Jonathan ^c   Bennett, Mark ^b  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

^c UNIVERSITY OF WATERLOO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; DRUG DERIVATIVE; FRUCTOSE; TOPIRAMATE;

ADULT; ARTICLE; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; COMORBIDITY; DRUG ADMINISTRATION; FEMALE; HEADACHE; HOSPITALIZATION; HUMAN; MALE; MENTAL DISEASE; MIDDLE AGED; ONSET AGE; PARESTHESIA; PHOBIA; PSYCHOLOGICAL ASPECT; PSYCHOLOGICAL RATING SCALE; TREATMENT OUTCOME; WEIGHT REDUCTION;

ADULT; AGE OF ONSET; ANTICONVULSANTS; COMORBIDITY; DRUG ADMINISTRATION SCHEDULE; FEMALE; FRUCTOSE; HEADACHE; HUMANS; MALE; MENTAL DISORDERS; MIDDLE AGED; PARESTHESIA; PHOBIC DISORDERS; PSYCHIATRIC STATUS RATING SCALES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 13744258074     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v65n1213     Document Type: Article

References (44)

1. Gelernter CS, Uhde TW, Cimbolic P, et al. Cognitive-behavioral and pharmacological treatments of social phobia: a controlled study. Arch Gen Psychiatry 1991;48:938-945
2. Liebowitz MR, Schneier P, Campeas R, et al. Phenelzine vs atenolol in social phobia: a placebo-controlled comparison. Arch Gen Psychiatry 1992;49:290-300
3. Heimberg RG, Liebowitz MR, Hope DA, et al. Cognitive behavioral group therapy vs phenelzine therapy for social phobia: 12-week outcome. Arch Gen Psychiatry 1998;55:1133-1141
4. Fahlen T, Nilsson HL, Borg K, et al. Social phobia: the clinical efficacy and tolerability of the monoamine oxidase-A and serotonin uptake inhibitor brofaromine. Acta Psychiatr Scand 1995;92:351-358
5. van Vliet IM, den Boer JA, Westenberg HGM, et al. Psychopharmacological treatment of social phobia: clinical and biochemical effects of brofaromine, a selective MAO-A inhibitor. Eur Neuropsychopharmacol 1992;2:21-29
6. Versiani M, Nardi AE, Mundim FD, et al. The long-term treatment of social phobia with moclobemide. Int Clin Psychopharmacol 1996;11 (suppl 3):83-88
7. Davidson JRT, Potts NS, Richichi E, et al. Treatment of social phobia with clonazepam and placebo. J Clin Psychopharmacol 1993;13:423-428
8. Versiani M, Nardi AE, Figueira I, et al. Double-blind placebo-controlled study of bromazepam in social phobia. Serie Psicofarmacologia 59. J Bras Psiquiatr 1997;46:167-171
9. van Vliet IM, den Boer JA, Westenberg HG. Psychopharmacological treatment of social phobia: a double-blind placebo controlled study with fluvoxamine. Psychopharmacology (Berl) 1994;115:128-134
10. Stein MB, Fyer AJ, Davidson JRT, et al. Fluvoxamine treatment of social phobia (social anxiety disorder): a double-blind, placebo-controlled study. Am J Psychiatry 1999;156:756-760
11. Davidson JRT, Hemby LW, Barbato L, et al. Fluvoxamine controlled release for the treatment of generalized social anxiety disorder. In: Programs and Abstracts of the annual meeting of the American College of Neuropsychopharmacology; Dec 10-14, 2000; San Juan, Puerto Rico
12. Katzelnick DJ, Kobak KA, Greist JH, et al. Sertraline for social phobia: a double-blind, placebo-controlled crossover study. Am J Psychiatry 1995;152:1368-1371
13. Van Ameringen MA, Lane RM, Walker JR, et al. Sertraline treatment of generalized social phobia: a 20-week, double-blind, placebo-controlled study. Am J Psychiatry 2001;158:275-281
14. Blomhoff S, Haug TT, Hellstrom K, et al. Randomised controlled general practice trial of sertraline, exposure therapy, and combined treatment in generalised social phobia. Br J Psychiatry 2001;179:23-30
15. Stein MB, Liebowitz MR, Lydiard RB, et al. Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial. JAMA 1998;280:708-713
16. Baldwin D, Bobes J, Stein DJ, et al, on behalf of the Paroxetine Study Group. Paroxetine in social phobia/social anxiety disorder: randomised, double-blind, placebo-controlled study. Br J Psychiatry 1999;175: 120-126
17. Davidson JRT. Pharmacotherapy of social anxiety disorder. J Clin Psychiatry 1998;59 (suppl 17):47-51
18. Allgulander C. Paroxetine in social anxiety disorder: a randomized placebo-controlled study. Acta Psychiatr Scand 1999;100:193-198
19. Pande AC, Davidson JRT, Jefferson JW, et al. Treatment of social phobia with gabapentin: a placebo-controlled study. J Clin Psychopharmacol 1999;19:341-348
20. Feltner DE, Pollack MH, Davidson JRT, et al. A placebo-controlled studyof pregabalin in the treatment of social phobia. In: Programs and Abstracts of the Anxiety Disorders Association of America's 20th Annual Conference; March 2000; Washington, DC
21. Biton V, Edwards KR, Montouris GD, et al. Topiramate titration and tolerability. Ann Pharmacother 2001;35:173-179
22. Marcotte D. Use of topiramate, a new anti-epileptic as a mood stabilizer. J Affect Disord 1998;50:245-251
23. Dursun SM, Devarajan S. Accelerated weight loss after treating refractory depression with fluoxetine plus topiramate: possible mechanisms of action? [letter] Can J Psychiatry 2001;46:287-288
24. Shapira NA, Goldsmith TD, McElroy SL. Treatment of binge-eating disorder with topiramate: a clinical case series. J Clin Psychiatry 2000; 61:368-372
25. Schneiderman JH. Topiramate: pharmacokinetics and pharmacodynamics. Can J Neurol Sci 1998;25:S3-S5
26. First MB, Spitzer RL, Gibbon M, et al. Structured Clinical Interview for DSM-IV Axis I Disorders, Patient Edition (SCID-I/P, version 2.0). New York, NY: Biometric Research, New York State Psychiatric Institute; 1995
27. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-389
28. Beck AT, Ward CH, Mendelson M, et al. An inventory for measuring depression. Arch Gen Psychiatry 1961;4:561-571
29. Beck AT, Epstein N, Brown G, et al. An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol 1988;56: 893-897
30. Connor KM, Davidson JR, Churchill LE, et al. Psychometric properties of the Social Phobia Inventory (SPIN): new self-rating scale. Br J Psychiatry 2000;176:379-386
31. Mattick RP, Clarke JC. Development and validation of measures of social phobia scrutiny fear and social interaction anxiety. Behav Res Ther 1998; 36:455-470
32. Sheehan DV. The Anxiety Disease. New York, NY: Scribner; 1983
33. Guy W, ed. ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health; 1976:218-222
34. Liebowitz MR. Social phobia. Mod Probl Pharmacopsychiatry 1987;22: 141-173
35. Kinrys G, Pollack MH, Simon NM, et al. Valproic acid for the treatment of social anxiety disorder. Int Clin Psychopharmacol 2003;18:169-172
36. Van Ameringen M, Mancini C, Styan G, et al. Relationship of social phobia with other psychiatric illnesses. J Affect Disord 1991;21:93-99
37. Schneier FR, Johnson J, Hornig CD, et al. Social phobia: comorbidity and morbidity in an epidemiologic sample. Arch Gen Psychiatry 1992; 49:282-288
38. Kessler RC, Stang P, Wittchen HU, et al. Lifetime co-morbidities between social phobia and mood disorders in the US national comorbidity survey. Psychol Med 1999;29:555-567
39. Stein MB, Pollack MH, Mangano R. Long-term treatment of generalized SAD with venlafaxine extended release. Presented at the 156th annual meeting of the American Psychiatric Association; May 17-22, 2003; San Francisco, Calif
40. Lepola U, Bergtholdt B, Lambert J, et al. Controlled-release paroxetine in the treatment of patients with social anxiety disorder. J Clin Psychiatry 2004;65:222-229
41. Rosenberg DR, MacMaster FP, Keshavan MS, et al. Decrease in caudate glutamatergic concentrations in pediatric obsessive-compulsive disorder patients taking paroxetine. J Am Acad Child Adolesc Psychiatry 2000;39: 1096-1103
42. Mathew SJ, Coplan JD, Gorman JM. Neurobiological mechanisms of social anxiety disorder. Am J Psychiatry 2001;158:1558-1567
43. Shekhar A, Keim SR. LY354740, a potent group II metabotropic glutamate receptor agonist prevents lactate-induced panic-like response in panic-prone rats. Neuropharmacology 2000;39:1139-1146
44. Klodzinska A, Chojnacka-Wojcik E, Palucha A, et al. Potential anti-anxiety, anti-addictive effects of LY 354740, a selective group II glutamate metobotropic receptors agonist in animal models. Neuropharmacology 1999;38:1831-1839